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Recent studies suggest that TJ-41, a herbal drug, possesses chemotherapeutic eﬀects. Accordingly, this study was undertaken to
investigate the anticarcinogenic eﬀects of TJ-41 on human breast cancer cells lines. TJ-41 inhibited the proliferation of human
breast cancer cell lines dose dependently. Flow cytometric analysis showed that this decrease in DNA synthesis is to be associated
with induction of apoptosis. In both cell lines, apoptosis was abolished by caspase-9 inhibitor Z-LEHD-fmk but was weakly
inhibited by caspase-8 inhibitor Z-IETD-fmk, indicating that caspase-9 activation was involved in TJ-41 induced apoptosis.
Additionally, TJ-41 stimulated phosphorylation of c-Jun NH2-terminal kinase (JNK) and pretreatment of breast cancer cells with
JNK inhibitor SP600125 completely abolished TJ-41 induced apoptosis. Our data also demonstrate that combined treatment of
TJ-41 and 5-FU signiﬁcantly potentiates the apoptotic eﬀects of 5-FU in both breast cancer cell lines. Taken together, these data
suggest that TJ-41 might provide a novel chemotherapeutic treatment for breast cancer.
Copyright © 2009 Suresh Volate et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Despite centuries of theoretical meandering and scientiﬁc
inquiry, breast cancer (BrCa) continues to represent a bur-
geoningmedicalproblem[1].AccordingtotheWorldHealth
Organization, more than 1.2 million people will be diag-
nosed with breast cancer each year worldwide. The average
lifetime risk of BrCa for newborn U.S. females is 12%, and
this risk is much higher in patients with certain risk factors
such as early menarche, nullparity, and late menopause [2].
The American Cancer Society estimates that in this year 216
000 new cases of breast cancer will be diagnosed and that
roughly 40 000 women will die of this disease. A major eﬀort
to reduce breast cancer mortality and morbidity is focused
on development of better breast cancer treatments.
In the past few years, it has become apparent that cancer
patients are actively seeking complementary/alternative
approaches to serve either adjunctively with allopathic
chemotherapy or singly as a replacement for primary
therapy. In a recent study assessing the prevalence of
complementary and alternative medicine (CAM) in a
comprehensive cancer center, 83.3% of patients had used at
least 1 CAM approach and 62.6% had used vitamins and
herbs [3]. A number of recent studies support the eﬃcacy
and safety of some herbal formulas. In addition, these
studies have shown that these remedies worked eﬀectively
in some instances in which conventional Western therapies
failed or proved to be insuﬃcient to provide a palliative cure.
For example, a randomized, nonblind, controlled clinical
trial conducted in Japan showed that sho-saiko-to, an extract
of seven Chinese herbs, helps preventing liver cancer in
patients with cirrhosis [4].
The use of Chinese herbal drugs, which have an extensive
history of use (3000 yrs in China) has now been increasing
in recent years because of their safety and few side eﬀects [5].
Many herbal formulas are believed to have tonic eﬀects to
body function. Among them, TJ-41, named Bu-Zhong-Yi-
Qi-TanginChinaandHochu-Ekki-ToinJapan,isconsidered
to be the best at nourishing the vital energy-Qi [6]a n d
antagonizing the adverse eﬀects caused by chemotherapy [7–
9]. Cell cultures [10], animal studies [11], and clinical trials
have demonstrated that TJ-41 formula may inhibit tumor
cell proliferation, enhance immune activity of lymphocytes,
and improve cancer patients’ well being [12]. Accordingly,2 Journal of Oncology
the ﬁrst objective of this study was to characterize the eﬀects
of TJ-41 on hormone sensitive and insensitive breast cancer
cell lines (MCF-7 and MDA-MB-231, resp.).
5-ﬂuorouracil (5-FU) is a DNA damaging drug that is
commonly used as a chemotherapeutic agent that inhibits
cancer growth by initiating apoptosis. 5-FU initiates apop-
tosis by targeting thymidylate synthase (TS), and by direct
incorporation of 5-FU metabolites into DNA and RNA
[13]. This drug has been commonly used to treat various
types of cancer including breast, head, stomach, and colon
cancer. Ideally, chemotherapeutic drugs should speciﬁcally
target only cancerous cells by inducing cytotoxic or cyto-
static eﬀects, thereby decreasing the tumor growth with-
out aﬀecting normal cells. The eﬀectiveness of traditional
chemotherapy has suﬀered due to the lack of speciﬁcity,
rapiddrugmetabolism,andbothintrinsicandacquireddrug
resistance as well as induction of side eﬀects due to high
dosage. This produces a transient decline in quality of life
of the patients. These problems could be overcome by a low-
dose treatment of drugs in combination with other natural
compounds/drugs,whichcouldenhancetheantiproliferative
eﬀects. Therefore, the second objective of the present study
was to explore the combined eﬀect of 5-FU and TJ-41 on
MCF-7 and MDA-MB-231 cell lines.
2.Methods and Materials
2.1. Preparation of TJ-41. TJ-41 was purchased from Xi’an
National Chinese Herbal Cooperation and consists of crude
standardized extract from ten herbs. The plant materials
and their speciﬁc ratio (in grams) as they are described
in the company literature are Astragalus membranaceus
(10.0g), Panax ginseng (10.0g), Atractylodes lancea rhizome
(10.0g),Angelicae sinensis (7.5g),Radixbupleuriroot (5.0g),
Glycyrrhiza glabra root (3.8g), Rhizome cimicifuga (2.5g),
Ziziphus zizyphus (5.0g), Citrus unshiu peel (5.0g), and
Zingiber oﬃcinale (1.3g). Seventy ﬁve grams of TJ-41 were
poured together for extraction in a glass container and
soaked for 24 hours with 2000mL tap-water in refrigerator.
The next day, the mixture was boiled for more than 35
minutes halving the original volume. The decoction was
ﬁltered through a colander while hot, and the volume
adjusted to 1000mL with water after cooling. The adjusted
decoction was centrifuged (8.000rpm for 10 minutes) and
the supernatant was sterilized by sequentially passing it
through 0.45-μm and 0.22-μm ﬁlter. The stock solution of
TJ-41 (75 mg/mL) was aliquoted into 50mL centrifuge tube
a n ds t o r e da t−20
◦C.
2.2. Cell Culture. The human breast adenocarcinoma ER+
(MCF-7) and ER− (MDA-MB-231) cell lines were obtained
from ATCC. MCF-7 cell line (estrogen receptor positive)w a s
derived from breast cancer pleural eﬀusion and MDA-MB
231 (estrogen receptor negative) was derived from the lung
metastases of another breast cancer patient. Cell lines were
gr o wninmo nola y e rcultur einDMEM(Dulbec c o ’ sM odiﬁed
Eagle’s Medium) supplemented with 10% (v/v) fetal calf
serum, and 1% (v/v) antibiotic-antimycotic agent. Cells were
g r o w nt oc o n ﬂ u e n c ea t3 7
◦C in a humidiﬁed atmosphere
containing 5% CO2 in air and were passaged weekly using
0.25% trypsin. The experiments were performed with cells
in the logarithmic phase of growth.
2.3. Proliferation Assay and Reversibility Study. Human
breast cancer (BrCa) cell lines were seeded at a density of
5 × 104/well in 24-well tissue culture dishes and allowed
to attach overnight. To synchronize the cell cycle, BrCa
cells were incubated in serum-free medium for 24 hours.
Triplicate samples of growing cells were treated with TJ-41
for time and concentrations as indicated in the experiments.
During the last 6 hours of treatment, cells were pulsed with
[3H]-Thymidine (1μCimL−1) and processed as reported
by Brandi et al. [14]. The results are expressed as mean
percentage of [3H]-Thymidine incorporation from triplicate
w e l l sa sc o m p a r e dw i t hc o n t r o lu n t r e a t e ds a m p l e s .F o rt h e
reversibility study, both MCF-7 and MDA-MB-231 BrCa
cells were treated exactly as described above except, after
synchronization of cell cycle they were incubated with
375μg/mL of TJ-41. After 2 days, the medium was removed
and the cells were further incubated in a fresh drug-free
medium for 2 more days. During the experiment, medium
was replaced with a fresh drug-containing or drug-free
medium every 24 hours. At the end of incubation, cell pro-
liferation was assessed by incorporation of [3H]-Thymidine
as described above. For this assay, each concentration (each
time) was performed in triplicates wells, and in at least 3
independent experiments.
2.4. Analysis of the DNA Content by Flow Cytometry
(Hypoploid Cells). MCF-7 and MDA-MB-231 cells were
seeded at a density of 5 × 105/well in six-well culture dishes.
To synchronize the cell cycle, BrCa cells were incubated
in serum-free medium for 24 hours. The cells were then
treated with or without 75μg/mL TJ-41 and 0.5μM 5-FU
(Sigma Aldrich Co. St. Louis, Mo, USA) and harvested after
48 hours by trypsinization. The cells were centrifuged at
2000rpm for 5 minutes, washed with phosphate-buﬀered
saline (PBS), ﬁxed with 70% ethanol, and then subjected to
ﬂowcytometricanalysis(EpiccsXL-MCL,BeckmanCoulter)
after propidium iodide labeling. This assay was performed
at least 3 independent times for each treatment group. For
each experimental condition a minimum of 3×104 cells was
analyzed. Data were acquired using Expo32Acquision soft-
ware (Applied Cytomety System, Beckman Coulter, Miami,
Fla). The percentage of cells with subdiploid DNA was
quantiﬁed by the Expo 32 ADC (Applied Cytomety System,
Beckman Coulter, Miami, Fla) software by plotting intensity
of ﬂuorescence versus number of cells. The percentage
of cells located to the left of the G1 peak, diagnostic of
hypodiploid cells that have lost DNA, was taken as the
percentage of apoptotic cells [15]. For the experiments that
use inhibitors, cells were pretreated with 10μMo fJ N K
inhibitor SP600125, or caspase-9 speciﬁc inhibitor Z-LEHD-
fmk, or 10μM caspase-8 speciﬁc inhibitor Z-IETD-fmk for 2
hours before TJ-41 treatment and assessment of apoptosis.
All the inhibitors used in this experiment were purchased
from Calbiochem San Diego, Calif, USA.Journal of Oncology 3
2.5.PreparationofCytosolicExtractsandWesternBlotAnalysis
of Cytochrome c Release. BrCa cells were washed twice with
ice-cold PBS and scraped oﬀ the plates. Cells were collected
by centrifugation at 500g for 10 minutes. The cell pellet
was resuspended in 500μLo fe x t r a c t i o nb u ﬀer containing
210mM mannitol, 70mM sucrose, 20mM HEPES-KOH,
50mM KCL, 5mM EGTA, 2mM MgCl2, 1mM dithiothre-
itol, 0.1mM phenylmethylsulfonyl ﬂuoride, and protease
inhibitors (Complete Cocktail; Roche Molecular Biochemi-
cals, Indianapolis, Ind). After incubation on ice for 30 min-
utes, cells were sonicated for 30 seconds. Homogenates were
centrifuged at 12.000 × gf o r5m i n u t e sa t4 ◦C. Supernatants
were collected and further centrifuged at 100.000 × gf o r
30 minutes at 4◦C to yield cytosol. Twenty-ﬁve micrograms
of total protein, as determined by the Bradford method
(Bio-Rad), were resolved on 12% SDS-polyacrylamide gel
electrophoresis and transferred to polyvinylidene diﬂuoride
(PVDF) membrane. Membrane was blocked with 5% nonfat
dry milk in TBS (20mM Tris-HCL, 8g/L NaCl, pH 7.4) for
1 hour at room temperature, followed by incubation with
1μg/mL primary monoclonal anticytochrome c antibody in
TBScontaining5%nonfatmilkovernightat4◦C.Membrane
waswashedthree times with TBSandblotted with secondary
antibody conjugated with horseradish peroxidase (1:10.000
dilution, Cell Signaling Technology, Danvers, Mass) at room
temperature for 30 minutes. The proteins were visualized
using ECLplus (Enhanced Chemiluminescence, Amersham,
Piscataway, NJ) after washing three times in TBS.
2.6. Western Blotting to Examine Phosphorylation of JNK.
After treatments, BrCa cells were washed with ice-cold
PBS and lysed with 500μLo fl y s i sb u ﬀer (10mM Tris-
HCL, pH 7.4, 50mM sodium chloride, 30mM sodium
pyrophosphate, 50mM sodium ﬂuoride, 100mM sodium
orthovanadate, 2mM iodoacetic acid, 5mM zinc chloride,
1mM phenylmethylsulfonyl ﬂuoride, and 0.5% Trition-×
100).Thelysateswerehomogenizedbypassingthrougha22-
G needle three times, and kept on ice for 30 minutes. The
homogenates were centrifuged at 12 000g for 15 minutes
at 4◦C. The protein concentration of whole cell lysates
was determined by Bio-Rad protein assay kit. An equal
amount of protein (50μg) was then resolved on a 10% SDS-
polyacrylamide gel and transferred to PVDF membrane. The
membrane was blocked in 5% nonfat dry milk in TBS for 1
hour at room temperature then incubated overnight at 4◦C
with 10μL of anti-phospho-JNK (Thr 183/Tyr185) (1 : 5000
dilution, Cell Signaling Technology). After hybridization
with primary antibody, the membrane was washed with TBS
for three times, then incubated with horseradish peroxidase-
conjugated secondary antibody (1 : 10 000 dilution, Cell
Signaling Technology) for 30 minutes at room temperature
and washed with TBS three times. Final detection was
performed with ECL reagents (Amersham, Piscataway, NJ).
2.7. Statistical Analysis. All data were analyzed using Sig-
mastat software (SPSS, Chicago, IL). All treatments were
compared with no treatment or 5-FU treated group using
one-way ANOVA. If the variance was equal and a signiﬁcant
diﬀerence (P<. 05) was observed, the Holm-Sidak method
asamultiplecomparisonversuscontrolgroupwasused[16].
For data with unequal variance, the Kruskal-Wallis one-way
ANOVA on ranks was used. If a signiﬁcant diﬀerence (P<
.05) was observed, multiple comparisons versus the control
group were performed using the Dunn’s method.
3. Results
3.1. Antiproliferative Eﬀect of TJ-41 on BrCa Cell Lines.
We ﬁrst investigated the eﬀect of TJ-41 on the growth of
estrogen receptor positive (MCF-7) and estrogen receptor
negative (MDA-MB-231) breast cancer cell lines in vitro
by measuring 3H-Thymidine incorporation. As shown in
Figure 1(a), exposing these cell lines to TJ-41 for 48 hours
induced a dose-dependent decrease in cell proliferation
compared with proliferation of untreated cells. TJ-41 at a
concentration of 75μg/mL caused a 50% and 57% growth
inhibition in MDA-MB-231 and MCF-7 cells, respectively.
Wealsoexaminedthetime-responserelationshipofTJ-41on
both the cell lines (data not shown). Incubating these cells
with media containing TJ-41 for 24, 48, and 72 hours had
similar inhibition in cell growth, and the results were not
statistically signiﬁcant.
To further characterize the eﬀects of TJ-41 on BrCa cell
lines,weconductedexperimentstoseeiftheantiproliferative
eﬀectswerereversible.WhenMCF-7andMDA-MB-231cells
were exposed to 375μg/mL of TJ-41 for 48 hours, the growth
rate was diminished by 72% for MCF-7 (P<. 05) and 74%
for MDA-MB-231 (P<. 05). Upon removal of the drug
for 2 days, the growth rate increased, albeit still at a slower
rate for the initial 48 hours (Figure 1(b)). Taken together,
these results clearly demonstrate that TJ-41 exerts a dose-
dependent antiproliferative eﬀect on BrCa cells and that
this response is reversible. Importantly, this antiproliferative
eﬀect is ER-independent.
3.2. TJ-41 Enhances the Eﬃcacy of 5-Fluorouracil (5-FU). TJ-
41 is traditionally prescribed to relieve adverse eﬀects of
chemotherapy; therefore, we next conducted experiments to
evaluate whether TJ-41 can augment the antiproliferative
actions of 5-FU. To determine the cytotoxic activity of 5-
FU on MCF-7 and MDA-MB-231 cells, dose-eﬀect experi-
ments were performed (data not shown). For the combined
experiments suboptimal doses of 5-FU (0.5μM) and TJ-41
(75μg/mL) were used. As shown in Figure 2,t r e a t m e n to f
both MCF-7 and MDA-MB-231 cells with 5-FU (0.5μM)
for 48 hours markedly reduced the amount of incorporated
[3H]-Thymidine by approximately 41% for MCF-7 (P<
.001)and59%forMDA-MB-231(P<. 001).Whencellswere
cotreated with 5-FU and TJ-41 they measured 51% and 73%
(P<. 001) in MCF-7 and MDA-MB-231, respectively. These
resultsindicatedthatTJ-41mayenhancetheantiproliferative
ability of 5-FU in both ER+ and ER− BrCa cell lines.
3.3. TJ-41 Induces Apoptosis and Potentiates the Apoptotic
Eﬀects of 5-FU. To determine the mechanism of TJ-41
induced growth inhibition, we studied the eﬀects of test
compounds with respect to the induction of apoptosis in
the BrCa cells. MCF-7 and MDA-MB-231 cells were grown4 Journal of Oncology
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Figure1:EﬀectofTJ-41onthegrowthofhumanBrCacelllines.(a)
Two BrCa cell lines (diﬀering in the estrogen receptor status) were
cultured in the presence of various concentrations (7.5–750μg/mL)
of TJ-41 for 48 hours. Cell proliferation was measured by 3H-
Thymidine incorporation in triplicate wells. Results of data derived
from three diﬀerent experiments are expressed as mean percentage
of 3H-Thymidine incorporation from triplicate wells as compared
tothatofcontrol(untreated)cells.Alldatashownarethemean±SD
o ft h r e es e p a r a t ee x p e r i m e n t s .( b )D e p i c t st h er e v e r s i b l ee ﬀects
of TJ-41 on BrCa Cell lines. MCF-7 and MDA-MB-231 cell were
cultured in the presence of 375μg / m LT J - 4 1f o r2d a y s .A f t e r2
days, the growth medium was substituted with fresh medium for
another 2 days. Cell proliferation was measured by 3H-Thymidine
incorporation in triplicate wells. Results of data derived from three
diﬀerent experiments are expressed as mean percentage of 3H-
Thymidine incorporation from triplicate wells as compared to that
of control (untreated) cells. All data shown are the mean ± SD of
three separate experiments.
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Figure 2: Eﬀects of TJ-41 on 5 FU-induced cell death on BrCa cell
lines. MCF-7 and MDA-MB-231 cells were treated with 0.5μMo f
5-FU alone and in combination with 75μg/mL TJ-41 for 48 hours.
Cell proliferation was measured by 3H-Thymidine incorporation
in triplicate wells. Results of data derived from three diﬀerent
experiments are expressed as mean percentage of 3H-Thymidine
incorporation from triplicate wells as compared to that of control
untreated cells. All data shown are the mean ± SD of three separate
experiments.
in twelve-well plates and were treated with TJ-41 and 5-
FU alone and in combination for 48 hours. Cell death
was assayed by propidium iodide staining and subjected to
ﬂow cytometric analysis. As shown in Figure 3,t r e a t m e n t
of MCF-7 and MDA-MB-231 cells with TJ-41 and 5-FU led
to a cell cycle phase distribution with a decrease of cells in
S-phase associated with a concomitant increase of the cell
portionpredominantlyinsub-G1 phase(Figures3(b)–3(g)).
Again, in both of the cell lines, combination of TJ-41 and 5-
FUcausedasigniﬁcantincreaseinthesub-G1 cellpopulation
(Figures 3(d) and 3(h)) compared to no treatment (Figures
3(a) and 3(e)). A histogram summarizing the percentage
of sub-G1fraction of cells is shown in Figure 4.F o rb o t h
BrCa cell lines, cotreatment of TJ-41 and 5-FU led to a
greater increase in the percentage of sub-G1 cell population
than either one alone. TJ-41 (75μg/mL) treatment produced
a signiﬁcant increase in the percentage of the sub-G1 cell
population(controlcells:4 ±1%forMCF-7and10 ±2%for
MDA-MB-231; TJ-41: 13 ± 9% for MCF-7 and 31 ± 5% for
MDA-MB-231). Similarly, the 5-FU treatment also produced
a signiﬁcant elevation of the sub-G1 cell population (control
cells: 4 ± 1% for MCF-7 and 10 ± 2% for MDA-MB-231;
5-FU: 15 ± 3% for MCF-7 and 36 ± 7% for MDA-MB-231).
When TJ-41 and 5-FU were combined, the increase in the
sub-G1 cell population was much more pronounced (controlJournal of Oncology 5
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Figure 3: Cell cycle kinetics of BrCa cells after treatment with TJ-41 and 5-FU. MCF-7 and MDA-MB-231 cells were treated with TJ-41 and
5-FU either alone or combined for 48 hours. DNA was stained with propidium iodide. The ﬁgure shows the cell cycle proﬁle of control cells
(a) and (e), TJ-41-treated cells (b) and (f), 5-FU treated cell (c) and (g), and TJ-41 and 5-FU combined (d) and (h). Results are from one
experiment that is representative of three similar ones.6 Journal of Oncology
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Figure 4:Theeﬀect of TJ-41and 5-FU treatment on apoptosis (sub
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cells:4±1%forMCF-7and10±2%forMDA-MB-231;TJ-41
+5-FU: 22±4% for MCF-7 and 56±8% forMDA-MB-231).
3.4. TJ-41 Induced the Release of Cytochrome c. To examine
the possible role of mitochondria in the apoptotic death
of MCF-7 and MDA-MB-231 cells induced by TJ-41, the
existenceofcytochromecinthecytosolicfractionofcelllysis
was measured. Treatment of cells for 48 hours with 75μg/mL
TJ-41 led to a dramatically increased amount of cytochrome
c leaking from mitochondrial membrane into cytosol in
both MCF-7 (Figure 5(a)) and MDA-MB-231 (Figure 5(b))
cells. Consistent with the ﬂow cytometric analysis, combined
treatment of 5-FU and TJ-41 led to a larger release of
cytochrome c.
3.5. TJ-41 Induced JNK Activation and Inhibition of JNK and
Caspase-9 Abrogates TJ-41-Induced Apoptosis. Since the JNK
pathway has been demonstrated to be required for apoptosis
caused by chemotherapeutic agents [17], it is conceivable
that the JNK pathway might also play a key role in TJ-41-
induced apoptosis in BrCa cells. To test this, we performed
WesternblotanalysistoexaminephosphorylationofJNK(p-
JNK) protein. The p-JNK protein expression was detectable
as early as 1 hour after TJ-41 treatment in both cell lines;
however, the activation peaked at ∼24 hours for MCF-7 cells
and 6 hours for MDA-MB-231 cells (Figure 6).
To further elucidate the apoptotic signaling pathway
triggered by TJ-41, we investigated the eﬀects of SP600125
(a JNK inhibitor), Z-IETD-FMK (a caspase-8 inhibitor),
and Z-LEHD-FMK (a caspase-9 inhibitor) on TJ-41 induced
cell death. Cells were analyzed by ﬂow cytometry, and
the extent of apoptosis was determined by measuring the
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Figure 5: Eﬀect of TJ-41 on the release of cytochrome c from
mitochondria. After treatment cytosolic extracts of BrCa cell
lines were prepared as described in the Materials and Methods.
Twenty-ﬁve micrograms of cytosolic protein were resolved on 12%
SDS-polyacrylamide gel electrophoresis and transferred to PVDF
membrane. Membrane was blocked with 5% nonfat dry milk in
TBS, followed by incubation with 1μg/mL primary monoclonal
anticytochrome c antibody in TBS containing 5% nonfat milk
overnight at 4◦C. The proteins were visualized using analyzed by
western blotting using anticytochrome c antibody.
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Figure 6: Eﬀect TJ-41 induced JNK activation.( a )M C F - 7a n d
(b) MDA-MB-231 cells were treated with 75μg/mL TJ-41 and cell
lysates were collected at the indicated times. Total cellular proteins
were isolated and Wstern blot were performed as described in the
MaterialsandMethod.Allsamplesingelsareequallyloadedat50μg
oftotalprotein,andβ-actinwasusedasaninternalcontrolforequal
protein loading.
fraction of cells with sub-G1 DNA content. As shown in
Figure 7, treatment of BrCa cells with the JNK inhibitor
SP600125 alone for 1 hour had negligible eﬀects on
apoptosis compared to the no treatment group. However,
when cells were treated with a combination of SP600125
(1 hour) and TJ-41 (47 hours), the percentage of cellsJournal of Oncology 7
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Figure 7: Eﬀects of SP600125 (a JNK inhibitor), Z-IETD-FMK (a
caspase-8 inhibitor), and Z-LEHD-FMK (a caspase-9 inhibitor) on
TJ-41-induced apoptosis in MCF-7 and MDA-MB-231 breast cancer
cell lines. BrCa cells were exposed to inhibitors for one hour prior
to the addition of TJ-41 (48 hours). Percent of cells undergoing
apoptosis (sub G1) was measured by ﬂow cytometry of propidium-
iodide stained DNA. Data represents mean ± SD of at least three
experiments. Signiﬁcant diﬀerences from untreated control are
indicated: ∗P<. 05, ∗∗P<. 002, and ∗∗∗P<. 001.
undergoing apoptosis was dramatically lower than those
with TJ-41alone, indicating that inhibition of JNK activation
protects against the apoptotic eﬀects of TJ-41. Similarly,
combined treatment of cells with the caspase-9 inhibitor Z-
LEHD-FMK and TJ-41 led to marked decrease in the percent
of cell undergoing apoptosis. However, in the presence of
caspase-8 inhibitor Z-IETD-FMK, TJ-41’s proapoptotic
eﬀect was not aﬀected. Thus the activation of JNK and
caspase-9 but not caspase-8 is necessary and suﬃcient for
the induction of apoptosis in response to TJ-41 treatment.
4. Discussion and Conclusion
Breast cancer causes signiﬁcant morbidity and mortality
and is a major public problem in the United States
and increasingly in the developing world. Conventional
c h e m o t h e r a p e u t i cd r u g ss u c ha s5 - F l u o r o u r a c i l( 5 - F U )a r e
widely used in cancer therapy, but the nonspeciﬁcity and
acquired drug resistance as well as induction of side eﬀects
duetohighdosagechemoresistanceremainsamajorobstacle
in clinical settings. Therefore, much attention has been
focused on natural products as potential sources of novel
anticancer drugs over the last few decades [18]. With an
annual sale value of $52 million in Japan alone, TJ-41
is heavily prescribed to treat such conditions as general
fatigue and poor appetite to help promoting overall physical
recovery following operations. By nourishing the blood and
toningthegastrointestinal(GI)system,administrationofTJ-
41 has been reported to be able to supplement or relieve the
adverse events of cancer chemotherapy [19]. Although the
major uses of TJ-41 are to relieve stress and fatigue, boost
immunity, and speed up the recovery of total white-blood-
cell counts, this tonic formula may also have additional
chemopreventive or therapeutic eﬀects on breast cancer.
Here, we report that TJ-41 can eﬀectively inhibit hormone
sensitive and insensitive breast cancer cell lines (MCF-7 and
MDA-MB-231, resp.) and enhance the eﬃcacy of 5-FU.
Invasive breast cancers can be divided into two subtypes
based on whether or not the tumor cells express estrogen
receptor (ER). The ER status is important because, when
circulating estrogen binds ER, it stimulates cell division and
tumor growth [20]. Many strategies have been developed
over the years to inhibit this estrogen-induced mitogenic
pathway. Numerous studies have shown that hormonal
therapies signiﬁcantly prolong life, although they rarely cure
patients with ER-positive (ER+) breast cancer, where the
mitogenic pathway is intact, but that they are ineﬀective in
ER-negative (ER−) disease, where the pathway is inactive
[20]. There are three general goals for better therapies in
breast cancer, improving therapies for ER+ disease, ﬁnding
therapies for ER− disease and, especially, broadening ther-
apies for prevention to include ER− disease. In the present
study, our results showed that the water-soluble ingredi-
ents of TJ-41, at a concentration of 75μg/mL, displayed
antiproliferative eﬀects on both MCF-7 (ER+) and MDA-
MB-231 (ER−) breast cancer cell lines. Importantly, this
antiproliferative eﬀect was reversible and independent of the
estrogen receptor status. The concentrations of TJ-41 used in
our experiments are the same as the blood concentrations
attained when 7.5g (the recommended dose) of TJ-41 is
administered orally. Among the components of TJ-41, cimi-
cifugarhizome (BrCa), glycyrrhizaroot (BrCa), and Ginseng
were reported to suppress the proliferation of breast cell lines
in vitro [21–23]. It is therefore reasonable to assume that the
direct inhibitory eﬀect of TJ-41 on the breast cancer cell lines
showninourstudymaybecausedbythoseactiveingredients
and perhaps additional as yet unidentiﬁed ingredients.
Recently, the pharmacological manipulation of growth
inhibition and antiproliferative eﬀect of malignant cells
through the induction of apoptosis have been recognized
as a novel strategy for the identiﬁcation and screening of
potential chemotherapeutic agents. Many chemotherapeutic
agents have been found to retain the activity of apoptosis
[25, 26]. The present study reveals that the growth inhibiting
eﬀects of TJ-41 appeared to be associated with the induction
of apoptosis (Figure 3). The TJ-41-induced apoptosis was
conﬁrmed by ﬂow cytometric analysis (Figures 3 and 4).
There are two pathways currently proposed to play
major roles in regulating apoptosis in mammalian cells: an
extrinsic pathway mediated by one or more death receptors
and an intrinsic pathway mediated by mitochondria [27].
In the extrinsic death receptor/ligands pathway, caspase
activation occurs as a direct consequence of death receptor
ligation, with upstream caspase-8 cleaving and activating
downstream proteases such as caspase-9 and caspase-3. In
the intrinsic mitochondrial pathway, Bax, a member of the
Bcl-2 family, plays the leading role. Bax normally resides in
the cytosol in a quiescent state. After an apoptotic stimulus,8 Journal of Oncology
Bax is translocated into the mitochondria and promotes the
release of cytochrome c [28] ,p o s s i b l yb yf o r m i n gap o r e
[29] or a voltage-dependent anion channel in the outer
mitochondrial membrane. Once in the cytosol, cytochrome
c activates Apaf-1, which then activates procaspase-9, which,
inturn,activatescaspase-3,triggeringapoptosis.Thecurrent
study found that TJ-41 caused the release of mitochondrial
cytochrome c in both cell lines. The fact that TJ-41-induced
cell death was reduced inhibitors speciﬁc for caspase-9
(Z-LEHD-fmk), but that cell death was not reduced by
exposure to Z-IETD-fmk, an inhibitor speciﬁc for caspase-8,
strongly suggests that the intrinsic mitochondrial pathway is
engaged in TJ-41-induced apoptosis.
Activation of the JNK pathway has been shown to
be a common phenomenon in apoptotic cell death [30–
33]; however, the importance of this activation seems to
vary in apoptosis caused by diﬀerent agents. The JNK
pathway is required for apoptosis induction by growth factor
withdrawal, heat shock, radiation, and ceramide [32, 34,
35]. In contrast, JNK may not be essential for receptor-
mediated apoptosis (e.g., Fas- and tumor necrosis factor-
mediated apoptosis) [36]. In this study, we demonstrate the
involvement of JNK in TJ-41-induced apoptosis by showing
that interfering with the JNK pathway suppressed TJ-41-
induced cell death. This result indicates that induction of
JNK activity is not a general event caused by stress during
cell death, but rather it is a speciﬁc phenomenon associated
with apoptotic cell death.
5-FU is the most active and widely used chemotherapeu-
ticagentforbreastcancer,witharesponserateof40%inpre-
viously untreated patients [37]. It intercalates between DNA
base pairs, induces DNA strand breaks, and inhibits DNA
biosynthesis and topoisomerase II activity [38]. It also forms
free radicals [39], which contribute to its cytotoxicity and
substantial antitumor activity [40, 41]. However, in majority
of the cases, 5-FU does not alleviate breast cancer and is
linked with signiﬁcant physiological and psychological side
eﬀects [42]. Additionally, the development of drug-resistant
phenotypes remains a signiﬁcant limitation to its clinical
use. The ﬁnding of natural inducers of apoptosis will be
the basis for the development of chemopreventive potential
natural materials [43]. Dietary constituents are known to
have a potential in chemoprevention and to be generally
safe.Anewfacetofchemopreventionresearchisdetermining
whether preventative agents can make chemotherapy work
better. This study has examined the molecular evidence
to prove chemotherapeutic eﬃcacy of the combination
treatment of anticancer agents and natural compounds in
order to develop the modalities to overcome drug resistance
and cytotoxic eﬀects of breast cancer treatment. Our study
demonstrates that TJ-41 enhances the susceptibility of MCF-
7 and MDA-MB-231 cells to 5-FU induced apoptosis. This
increase in apoptosis, compared to TJ-41 or 5-FU alone, was
conﬁrmed by ﬂow cytometric analysis as well as an increase
in caspase-3/7 activity (data not shown). The present study
fortheﬁrsttimeproposesthatTJ-41couldbeeﬀectivelyused
in combination with 5-FU.
In conclusion, we have demonstrated, for the ﬁrst time
that TJ-41, an Asian herbal mixture, exhibits a direct
TJ-41
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Figure 8: Proposed schema of molecular events involved in TJ-41
induced apoptosis in MCF-7 and MDA-MB-231 cell lines. Exposing
breast cancer cells to TJ-41 leads to environmental stress thus
triggers the activation of JNK. We speculate that phosphorylation
(activation) of JNK activates c-Jun which leads to the transcription
of proapoptotic Bcl-2 genes. The resulting Bcl-2 proteins are
translocated into the mitochondria and promotes the release of
cytochrome c, possibly by forming a pore or a voltage-dependent
anion channel [24] in the outer mitochondrial membrane. Once
in the cytosol, cytochrome c activates procaspase-9, which, in turn,
activates other “executioner” caspases such as caspase-3,- 6, and- 7,
as a result, committing cell to under going apoptosis.
inhibitory eﬀect on human breast cancer cell in vitro. The
inhibitory eﬀect can be attributed to the ability of TJ-41 to
induceapoptosis.Fromourresultswededucedthatexposing
TJ-41tobreastcancercellsleadstoenvironmentalstresswith
subsequent activation of JNK which in turn activates apop-
tosis via the mitochondrial pathway (Figure 8). Additionally,
combination of TJ-41 with 5-FU suggests potential thera-
peutic applications in breast cancer. Further investigations
on its possible clinical applications in breast cancer therapy
should be carried out, especially in regards to improving
chemotherapeutic outcomes of ER− breast cancers.
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